United Kingdom – Sequential, a pioneering leader in clinical microbiome research and testing, is reshaping the future of health and wellness by offering an unparalleled end-to-end platform designed for the personal care and novel therapeutics sectors. Through cutting-edge technology and a steadfast commitment to innovation, Sequential is advancing the understanding of the complex interplay between the human host and the microbiome, setting new benchmarks in human health research.

With a database of over 25,000 human microbiome samples, Sequential provides innovators with actionable insights into the impact of their products on the microbiome, enabling them to meet evolving consumer demands with precision. The company’s comprehensive suite of services includes microbiome testing, formulation support, claims certification, clinical assessments, and study recruitment.

“Our mission at Sequential is to unravel the intricate relationship between the microbiome and human health,” said Dr. Oliver Worsley, Co-founder and CEO of Sequential. “By leveraging advanced sequencing technologies and our vast database, we empower innovators to create innovative, science-backed products that redefine industry standards.”

A Comprehensive Approach to Microbiome Research

Sequential’s advanced platform is designed to meet the unique needs of the personal care and novel therapeutics industries. From early-stage product development to clinical validation, Sequential offers seamless support, ensuring that products are backed by robust scientific evidence.

Key Services Include:

1. Microbiome Testing: Cutting-edge sequencing technologies provide detailed insights into the composition and functionality of the microbiome.

• Targeted Skin Panel: The industry’s first-ever targeted skin microbiome panels, addressing key skin concerns through the lens of the microbiome.

1. Formulation Support: Collaborative development of microbiome-friendly products optimized for efficacy and safety.
2. Claims Certification: Independent verification of product claims to ensure compliance with industry standards.
3. Clinical Assessments: Rigorous testing methodologies to evaluate the performance of personal care and novel therapeutic products.
4. Study Recruitment: Efficient recruitment of study participants to ensure timely and reliable clinical studies.

Empowering Innovation in Personal Care and Novel Therapeutics

Sequential’s services are tailored to help innovators stand out in competitive markets by delivering evidence-based solutions. As consumers increasingly prioritize health and wellness, the demand for products that support microbiome health continues to grow. Sequential equips companies with the tools to meet this demand, fostering trust and credibility with consumers.

“Our extensive microbiome database and expertise in sequencing technologies allow us to deliver actionable insights,” added Dr. Worsley. “We’re proud to partner with our clients to bring groundbreaking products to market, enhancing both individual well-being and industry innovation.”

Setting New Standards in Science-Backed Product Development

By bridging the gap between scientific research and product development, Sequential is helping innovators create products that align with consumer expectations and regulatory requirements. Their approach not only strengthens their partners’ reputation but also contributes to advancing scientific understanding of the microbiome’s role in human health.

Sequential’s clients benefit from personalized support and a collaborative approach, ensuring that each product is optimized for success. Whether it’s developing a new skincare line or validating the efficacy of a novel topical therapeutic product, Sequential’s expertise provides a competitive edge.

For further information, please contact Dr. Worsley at team@sequential.bio.

About Sequential

Sequential is at the forefront of clinical microbiome research (skin, scalp, vaginal and oral), offering specialized testing and analysis services tailored to the personal care and novel therapeutic industries. With over 25,000 human microbiome samples in their database, Sequential delivers actionable insights that enable companies to innovate and lead in their respective markets. Their commitment to scientific excellence and customer success makes Sequential a trusted partner for innovators looking to pioneer the future of microbiome-focused products. They are backed by Innovate UK Smart Grants, Enterprise Singapore, Corundum Systems Biology, SOSV, Scrum Ventures, and Metaplanet Holdings. Clients include Johnson & Johnson, Walgreens Boots Alliance, and 60 other leading clients in personal care and novel therapeutics.